Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate resources effectively. In 2025, staying ahead of these changes will be vital ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

Jeff Coller and Michelle Kim explain the origin of the Center and how getting low-cost RNA based molecules into the hands of academics drives innovation.